76 hasil untuk "Alfredo Addeo"
Menampilkan 1–20 · 0,65 detik · RSS
-
Artikel Jurnal
Treatment Options for Non-Small Cell Lung Cancer Harboring Uncommon *EGFR* Mutations
An epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) is the preferred first-line treatment of choice for patients with *EGFR*-mutated advanced non-small cell lung cancer (NSCLC), with gefitinib, erlotinib, afatinib, dacomitinib and osimertinib being commonly used in clinical…
-
Artikel Jurnal
Intrathecal Methotrexate and Craniospinal Radiotherapy Can Be an Effective Treatment of Carcinomatous Meningitis in Patients with Breast Cancer: Case Reports
Introduction: Carcinomatous meningitis in breast cancer occurs as a complication in up to 5% of all cases. It is a very devastating diagnosis, with a median patient survival of about 3 months. Treatment is very controversial, and different modalities of treatment have been used but none of them…
-
Artikel Jurnal
ESMO Updates the Guidelines for the Diagnosis of RET-Altered Cancer to Herald a New Era in Targeted Therapy
The RET gene encodes a tyrosine kinase receptor that regulates cell survival and proliferation by triggering key downstream pathways.1 RET gene mutations and RET gene fusions are involved in the pathogenesis of lung, thyroid and other cancers. Recently, in 2021, the European Society for Medical…
Juga tersedia di: DOAJ
-
Artikel Jurnal
Systemic Treatments for Unresectable Pleural Mesothelioma: A Review of the Literature
Malignant pleural mesothelioma (MPM) is a rare and aggressive cancer with a poor prognosis. Most patients have unresectable disease at the time of diagnosis, for which palliative chemotherapy has been the standard of care for years. Despite the effort to improve systemic treatment, the prognosis…
Juga tersedia di: DOAJ
-
Artikel Jurnal
First-line alectinib for ALK-positive lung cancer: is there room for further improvement?
In the present editorial we describe the therapeutic achievements in the treatment of patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC). We focus on the major breakthroughs we have been witnessing in this context, from the introduction of crizotinib…
-
Artikel Jurnal
Treatment with Ipilimumab: A Case Report of Complete Response in a Metastatic Malignant Melanoma Patient
Introduction: Over the past year, 3 agents have been approved for the treatment of melanoma by the Food and Drug Administration. These include pegylated interferon α-2b for stage III melanoma, vemurafenib for unresectable or metastatic melanoma with BRAF V600E mutation, and ipilimumab for…
-
Artikel Jurnal
The Landscape of Immunotherapy Resistance in NSCLC
Lung cancer is the leading cause of cancer mortality worldwide. Immunotherapy has demonstrated clinically significant benefit for non-small-cell lung cancer, but innate (primary) or acquired resistance remains a challenge. Criteria for a uniform clinical definition of acquired resistance have been…
-
Artikel Jurnal
Rethinking the Optimal Duration of Immune Checkpoint Inhibitors in Non-small Cell Lung Cancer Throughout the COVID-19 Pandemic
Immune checkpoint inhibitors (ICPIs) have revolutionized the management and prognosis of fit patients with advanced non-small cell lung cancer (NSCLC). Recently, the publication of 5-year survival rates has cemented the role of ICPIs in NSCLC. An ongoing challenge is to determine the optimal…
-
Artikel Jurnal
Landmark PALOMA and MARIPOSA Studies Reveal the Impact of Amivantamab Alone and Combined with Lazertinib in Advanced NSCLC
Mutations in the epidermal growth factor receptor (*EGFR*) gene are frequently detected in non-small cell lung cancer (NSCLC). The most common *EGFR* mutations include deletions in exon 19 (Ex19del) and point L858R mutations in exon 21. Among uncommon mutations, exon 20 insertions (Ex20ins) account…
-
Artikel Jurnal
Evolving Therapeutic Scenario of Stage III Non-Small-Cell Lung Cancer
Lung cancer remains the leading cause of cancer-related death with an incidence that continues to increase in both sexes and all ages. However, 80% to 90% of lung cancers are non-small cell lung cancer (NSCLC) and the remaining 10% to 20% are small cell lung cancer. Adenocarcinoma is the most…
-
Artikel Jurnal
Shifting Paradigms in First-Line Treatment of EGFR-Mutated NSCLC
The therapeutic landscape for epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) is rapidly advancing, with novel combination therapies emerging as potentially transformative approaches. This mini review article provides an overview of current first-line treatment…
-
Artikel Jurnal
COVID-19 and lung cancer: risks, mechanisms and treatment interactions
Cases of the 2019 novel coronavirus also known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continue to rise worldwide. To date, there is no effective treatment. Clinical management is largely symptomatic, with organ support in intensive care for critically ill patients. The…